Glipizide
Brand Names: Glucotrol
Methodology & AI Transparency ⓘ
Glipizide Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- 2 Real-world patient consensus: 79% patient "Worth It" rating across 14 anonymous logs for Glipizide (RxNorm 310490).
- 3 Typical cash cost range: Public pharmacy ledger: $5.46 low cash benchmark vs. $34.50 chain retail average ($0.1217/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Glipizide): nausea (9.8%), diarrhea (7.1%), constipation (7.9%).
Ask our AI Specialists anything about Glipizide
Glipizide Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Glipizide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
CLINICAL PHARMACOLOGY Mechanism of Action The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans, glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which glipizide lowers blood glucose during long-term administration has not been clearly established.
Pharmacokinetic profiling of Glipizide demonstrates an elimination half-life of Biphasic clearance with 11–19 hr terminal t½ under Glipizide maintenance with Systemic oral bioavailability of roughly 71%–83% following first-pass transit systemic bioavailability; clearance proceeds via hepatic enzymatic processing and renal clearance proportional to creatinine clearance (glipizide), reaching clinical onset within initial pharmacodynamic onset within 1–3 hrs (peak cmax) for glipizide.
Titration schedules for Glipizide (2.5 mg/1 Tablet, Film Coated, Extended Release → 5 mg/1 Tablet → 2.5 mg/1 Tablet → 10 mg/1 Tablet, Extended Release → 5 mg/1 Tablet, Film Coated, Extended Release) require excluding contraindications glipizide is contraindicated in patients with: 1.; known hypersensitivity to the drug.; type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma.; real-world patient logs highlight nausea (9.8% of reports), constipation (7.9% of reports), diarrhea (7.1% of reports) alongside a 79.00% Worth-It consensus.
Combining Glipizide with MAOIs within a 14-day washout window risks severe serotonergic or pressor toxicity.
Avoid overlapping sulfonylurea prescriptions alongside Glipizide to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Glipizide is contraindicated in patients with: 1.
- Known hypersensitivity to the drug.
- Type 1 diabetes mellitus, diabetic ketoacidosis, with or without coma.
Logged Side-Effect Incidence (14 Reports)
Glipizide Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Glipizide)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes: What a 406-Participant Study Found Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less low blood sugar than glipizide in type 2 diabetes inadequately controlled with metformin. Diabetes care • 2011-09-15 • Randomized Controlled Trial | N = 406 | 93/100 | PMID 21816980 ↗ |
| Can This Approach Help? Inside the Latest Research on One year comparative trial of metformin and glipizide in type 2 Both drugs caused a similar reduction in albumin excretion rates. Diabete & metabolisme • 1994-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 7843470 ↗ |
Glipizide Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.1217/unit (~$3.65/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $5.46 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $7.50 / mo | View logs ↓ |
Glipizide Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Glipizide RxNorm Concept ID | 310490 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.1217 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $5.46 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 79.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Glipizide Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Glipizide: FDA labeling (2024-10-04, NDC 72162-2103), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Glipizide community threads and patient logs by age, biological sex, dosage, and treatment duration.